Managing for Growth from Start-Up to Initial Public Offering
First Statement of Responsibility
by Martin Grossmann.
.PUBLICATION, DISTRIBUTION, ETC
Place of Publication, Distribution, etc.
Heidelberg
Name of Publisher, Distributor, etc.
Physica-Verlag HD : Imprint : Physica
Date of Publication, Distribution, etc.
2003
PHYSICAL DESCRIPTION
Specific Material Designation and Extent of Item
(xvi, 323 pages 95 illustrations)
SERIES
Series Title
Contributions to management science.
CONTENTS NOTE
Text of Note
Independent Biopharmaceutical Companies and Their Specialization in Drug Discovery Technologies --; Model Structure for High-Technology Firms and Its Dynamic Behavior in Start-Up Phases --; Model Structure and Dynamic Behavior for High-Technology Firms in Transition to Growth Phases --; Economic Value Creation in Transition Phases: Access to Equity Capital --; Strategies for Growth Phases to Sustain Independence.
SUMMARY OR ABSTRACT
Text of Note
Research and development of novel medicines for human therapy commonly takes over a decade before significant revenues from sales are forthcoming. How can biotechnology companies be founded and grow successfully in an industry with such extended innovation processes? The book investigates this problem and distinguishes three growth phases: From incorporation and start-up through collaborative R & D with large pharmaceutical firms to value creation from R & D pipelines to Public Offerings and product marketing. In this book a dynamic simulation model for testing different decision-making strategies is developed. For each phase the author identifies decision rules that provide for successful corporate growth.